R. Taylor (Dunedin, New Zealand), S. Dragonieri (Bari, Italy)
Circulating microparticles in COPD exacerbations
J. Lascano, N. Kaipust, J. Lanfranco, M. Cearras, F. Caceres, C. Bidot, M. Gonzalez, W. Jy, Y. Ahn, M. Salathe, M. Campos (Miami, United States Of America)
|   |
Increased levels of angiopoientin-1, angiopoientin-2 in sputum supernatant in severe refractory asthma
E. Tseliou, P. Bakakos, G. Hillas, V. Bessa, V. Delimpoura, K. Mantzouranis, D. Simoes, S. Papiris, S. Loukides (Athens, Greece)
|  |
Exhaled nitric oxide level and atherosclerosis: The secret comes to fruition II
D. L. Tarnoki, A. D. Tarnoki, M. A. Stazi, E. Medda, R. Cotichini, C. Baracchini, Z. Garami, G. Meneghetti, L. Littvay, A. A. Molnar, K. Karlinger, F. Fanelli, V. Berczi, Z. Lazar, I. Horvath (Budapest, Hungary; Rome, Padua, Italy; Houston, United States Of America)
| |
The need for a personal target value for NO in allergic asthma
M. Högman, P. Meriläinen (Gävle, Uppsala, Sweden)
| |
Late Breaking Abstract: TLR9 agonist CYT003-QbG10 is safe and efficacious in persistent allergic asthma: A double-blind, placebo-controlled phase II study
K. M. Beeh, C. Schilder, F. Wagner, F. Kanniess, I. Naudts, A. Hammann, J. Willers, M. Bachmann, W. Renner (Wiesbaden, Eisenach, Berlin, Luebeck, Rodgau, Germany; Schlieren, Switzerland)
| |
Proteomic analysis of exhaled endogenous particles non-invasively sampled from the airways
A. Bredberg, J. Gobom, A. C. Almstrand, P. Larsson, A. C. Olin, E. Mirgorodskaya (Sweden)
| |
Breath analysis for discriminating and phenotyping COPD and asthma
B. Ibrahim, M. Basanta, P. Cadden, M. Morris, D. Singh, A. Woodcock, S. Fowler (Manchester, United Kingdom)
| |
External validation of exhaled breath molecular profiling in identifying COPD and asthma
N. Fens, A. C. Roldaan, E. H. Bel, P. J. Sterk (Amsterdam, Den Haag, Netherlands)
| |